To evaluate the possibility of specifically targeting CD38 and plasma cells in patients with autoimmune disease, we evaluated the expression of CD38 across a spectrum of immune cell subpopulations in human PBMC samples. The gene discussed is CD38; the disease is autoimmune disease.